Cross John Harry III 4
4 · Senti Biosciences, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
Cross John Harry III
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-03-07+174,200→ 174,200 totalExercise: $3.52Exp: 2035-03-06→ Common Stock (174,200 underlying)
Footnotes (1)
- [F1]25% of the shares underlying this option vest on March 3, 2026 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.